1. Journal Papers

This table browses all dspace content
Issue DateTitleJournal Title
2025BACES score: a predictor of health-related quality of life and associated factors in patients with nontuberculous mycobacterial pulmonary disease SCIENTIFIC REPORTS
2025Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0 CLINICAL AND MOLECULAR HEPATOLOGY
2025Trends and management of acute respiratory failure in hospitalized patients: a multicenter retrospective study in South Korea ACUTE AND CRITICAL CARE
2025Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyNEW ENGLAND JOURNAL OF MEDICINE
2025Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung CancerNEW ENGLAND JOURNAL OF MEDICINE
2025Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset LUNG CANCER
2025ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJCO PRECISION ONCOLOGY
2025Discovery of BBT-176 as a fourth-generation EGFR tyrosine kinase inhibitorResults in Chemistry
2025Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer LUNG CANCER
2025Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA FUTURE ONCOLOGY
2025Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A JOURNAL OF THORACIC ONCOLOGY
2025Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study JOURNAL OF CLINICAL ONCOLOGY
2025Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC CANCERS
2025First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial JOURNAL OF CLINICAL ONCOLOGY
2025Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib ANNALS OF ONCOLOGY
2025A new formula consisting of the five-factor score and earliest vasculitis damage index at diagnosis for predicting poor outcomes of antineutrophil cytoplasmic antibody-associated vasculitis FRONTIERS IN MEDICINE
2025Prognostic implication of venoarterial extracorporeal membrane oxygenation in acute myocardial infarction-related cardiogenic shockJOURNAL OF INTENSIVE CARE
2025Loss of p300 in proximal tubular cells reduces renal fibrosis and endothelial-mesenchymal transition EMBO MOLECULAR MEDICINE
2025Updates on lung cancer screening for early detection KOREAN JOURNAL OF INTERNAL MEDICINE
2025Targeting iron regulatory protein 2 (IRP2) to disrupt iron metabolism enhances radiosensitivity through mitochondrial dysfunction in breast cancer cells CELL DEATH DISCOVERY

Recent Submissions

Browse

Links